for people ages 18-55 (full criteria)
at San Francisco, California and other locations
study started
estimated completion



This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks in participants with PPMS, in comparison to the approved 600 mg dose of ocrelizumab.

Official Title

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis


Participants will be treated for a minimum of 120 weeks in the double-blind phase. Upon positive primary results after the double-blind phase, an optional higher dose extension treatment (OLE phase) is planned for eligible participants. The OLE will be carried out for approximately 96 weeks. Participants will be followed for safety for 48 weeks thereafter. Participants whose B-cell levels still did not replete to their baseline level or the lower limit of normal (LLN), whichever is lower, will move into the B-cell monitoring (BCM) phase following the safety follow-up phase. The study will end when all participants who were not treated with an alternative B-cell depleting therapy have repleted their B-cells to the baseline value or the lower limit of normal.


Multiple Sclerosis Multiple Sclerosis, Chronic Progressive Sclerosis Methylprednisolone Ocrelizumab Histamine Antagonists Histamine H1 Antagonists Antihistamine Ocrelizumab Higher Dose Ocrelizumab Approved Dose


You can join if…

Open to people ages 18-55

  • Diagnosis of primary progressive multiple sclerosis (PPMS).
  • Expanded disability status scale (EDSS) score at screening and baseline, from 3 to 6.5 inclusive.
  • Score of >/= to 2.0 on the Functional Systems scale for the pyramidal system that was due to lower extremity findings.
  • Participants requiring symptomatic treatment for MS and/or physiotherapy must be treated at a stable dose. No initiation of symptomatic treatment for MS or physiotherapy within 4 weeks of randomization.
  • Participants must be neurologically stable for at least 30 days prior to randomization and baseline.
  • Disease duration from the onset of MS symptoms, less than 15 years in participants with an EDSS score at screening >5.0, less than 10 years in participants with an EDSS score at screening </=5.0.
  • Documented evidence of the presence of cerebrospinal fluid-specific oligoclonal bands.
  • For females of childbearing potential, agreement to remain abstinent or use adequate contraceptive methods.
  • For female participants without reproductive potential, may be enrolled if post-menopausal unless receiving a hormonal therapy for her menopause or if surgically sterile.

You CAN'T join if...

  • History of relapsing remitting or secondary progressive MS at screening.
  • Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials.
  • History of confirmed or suspected progressive multifocal leukoencephalopathy.
  • History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening.
  • Immunocompromised state.
  • Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization.
  • Inability to complete an MRI or contraindication to gadolinium administration.
  • Contraindications to mandatory pre-medications for IRRs.
  • Known presence of other neurologic disorders.
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study.
  • Significant, uncontrolled disease that may preclude participant from participating in the study.
  • History of or currently active primary or secondary, non-drug-related, immunodeficiency.
  • Pregnant or breastfeeding or intending to become pregnant.
  • Lack of peripheral venous access.
  • History of alcohol or other drug abuse within 12 months prior to screening.
  • Treatment with any investigational agent or treatment with any experimental procedure for MS.
  • Previous use of anti-CD20s if in the last 2 years before screening, or if B-cell count is not normal, or if treatment was stopped due to safety reasons or lack of efficacy.
  • Previous use of mitoxantrone, cladribine, atacicept, and alemtuzumab.
  • Previous treatment with any other immunomodulatory or immunosuppressive medication not already listed above without appropriate washout as described in the applicable local label.
  • If the washout requirements are not described in the applicable local label, then the wash out period must be five times the half-life of the medication.
  • Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation.
  • Any previous history of transplantation or anti-rejection therapy.
  • Treatment with intravenous (IV) immunoglobulin (Ig) or plasmapheresis within 12 weeks prior to randomization.
  • Systemic corticosteroid therapy within 4 weeks prior to screening.
  • Positive screening tests for active, latent, or inadequately treated hepatitis B
  • Sensitivity or intolerance to any ingredient of ocrelizumab.
  • Any additional exclusionary criterion as per ocrelizumab local label, if more stringent than the above.


  • University of California San Francisco
    San Francisco California 94117 United States
  • Stanford University Medical Center; Stanford Neuroscience Health Center
    Stanford California 94305 United States


not yet accepting patients
Start Date
Completion Date
Hoffmann-La Roche
Phase 3
Study Type
Last Updated